Padlock Therapeutics Obtains $23,000,000 Series A Financing Round

  • Feed Type
  • Date
  • Company Name
    Padlock Therapeutics
  • Mailing Address
    25 First Street Cambridge, MA 02141 USA
  • Company Description
    At Padlock, we’re taking a whole new approach to treating destructive autoimmune diseases by extinguishing autoantigens at their source instead of targeting the immune system like current medicines.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Padlock plans to use the proceeds from this financing to deepen its understanding of the role of protein-arginine deiminases (PADs) in autoimmune disease and to advance its pipeline of PAD-directed therapeutics.
  • M&A Terms
  • Venture Investor

Trending on Xconomy